LaFleur & Godfrey LLC grew its position in Zimmer Biomet Holdings Inc (NYSE:ZBH) by 8.8% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 36,320 shares of the medical equipment provider’s stock after buying an additional 2,935 shares during the quarter. LaFleur & Godfrey LLC’s holdings in Zimmer Biomet were worth $4,638,000 as of its most recent SEC filing.
Several other large investors have also recently modified their holdings of ZBH. Norges Bank acquired a new position in Zimmer Biomet during the 4th quarter worth approximately $188,005,000. JPMorgan Chase & Co. increased its position in Zimmer Biomet by 9.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 11,595,444 shares of the medical equipment provider’s stock worth $1,524,453,000 after purchasing an additional 1,033,717 shares in the last quarter. American Century Companies Inc. increased its position in Zimmer Biomet by 23.1% during the 4th quarter. American Century Companies Inc. now owns 5,425,619 shares of the medical equipment provider’s stock worth $562,745,000 after purchasing an additional 1,016,489 shares in the last quarter. Pennsylvania Trust Co increased its position in Zimmer Biomet by 9,730.5% during the 1st quarter. Pennsylvania Trust Co now owns 836,676 shares of the medical equipment provider’s stock worth $55,704,000 after purchasing an additional 828,165 shares in the last quarter. Finally, Boston Partners increased its position in Zimmer Biomet by 74.1% during the 4th quarter. Boston Partners now owns 1,083,978 shares of the medical equipment provider’s stock worth $112,430,000 after purchasing an additional 461,269 shares in the last quarter. Institutional investors own 89.64% of the company’s stock.
Shares of NYSE ZBH opened at $121.91 on Friday. The firm has a market cap of $25.07 billion, a P/E ratio of 15.96, a P/E/G ratio of 2.29 and a beta of 1.19. Zimmer Biomet Holdings Inc has a 12-month low of $96.99 and a 12-month high of $134.55. The company has a debt-to-equity ratio of 0.72, a quick ratio of 0.97 and a current ratio of 2.00.
The business also recently announced a quarterly dividend, which was paid on Tuesday, April 30th. Investors of record on Friday, March 29th were paid a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 0.79%. The ex-dividend date of this dividend was Thursday, March 28th. Zimmer Biomet’s dividend payout ratio is presently 12.57%.
In other Zimmer Biomet news, Director Michael J. Farrell acquired 2,000 shares of the stock in a transaction on Wednesday, February 13th. The shares were purchased at an average price of $123.62 per share, for a total transaction of $247,240.00. Following the completion of the acquisition, the director now owns 2,000 shares in the company, valued at approximately $247,240. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Arthur J. Higgins acquired 500 shares of the stock in a transaction on Friday, February 15th. The shares were acquired at an average price of $123.28 per share, for a total transaction of $61,640.00. Following the acquisition, the director now owns 2,400 shares of the company’s stock, valued at approximately $295,872. The disclosure for this purchase can be found here. Over the last three months, insiders have purchased 4,425 shares of company stock worth $550,506. 0.72% of the stock is owned by insiders.
A number of research firms recently issued reports on ZBH. TheStreet upgraded shares of Zimmer Biomet from a “c” rating to a “b-” rating in a research report on Friday, April 26th. Cantor Fitzgerald set a $135.00 price objective on shares of Zimmer Biomet and gave the stock a “buy” rating in a research report on Friday, April 26th. Needham & Company LLC upgraded shares of Zimmer Biomet from a “buy” rating to a “strong-buy” rating and upped their price objective for the stock from $146.00 to $155.00 in a research report on Wednesday, April 24th. Barclays upped their price target on shares of Zimmer Biomet from $113.00 to $117.00 and gave the company an “underweight” rating in a research report on Monday, April 15th. Finally, Zacks Investment Research cut shares of Zimmer Biomet from a “hold” rating to a “sell” rating in a research report on Saturday, April 13th. Four research analysts have rated the stock with a sell rating, eight have given a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company. Zimmer Biomet has a consensus rating of “Hold” and a consensus target price of $130.19.
TRADEMARK VIOLATION WARNING: “LaFleur & Godfrey LLC Has $4.64 Million Position in Zimmer Biomet Holdings Inc (NYSE:ZBH)” was reported by Baseball Daily News and is the property of of Baseball Daily News. If you are accessing this story on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this story can be read at https://www.baseballdailydigest.com/news/2019/05/10/lafleur-godfrey-llc-has-4-64-million-stake-in-zimmer-biomet-holdings-inc-zbh.html.
About Zimmer Biomet
Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.
Recommended Story: Market Capitalization
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.